While the Overweight rating suggests that Morgan Stanley continues to see Arcus Biosciences as a good investment, the reduction in the price target may reflect a more conservative view on the company's growth prospects or market conditions. This could lead to a neutral short-term impact on the stock as the positive rating is counterbalanced by the lower price target.